|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Howard Goodall,
Clinical Research Physican - Phase I Quotient Bioresearch, Clinical Services Having previously attained BMedSci in Pharmacology in 2002 Howard graduated in medicine from Edinburgh University Medical School in 2005. Howard worked in a range of medical and surgical fields and specialised in General and Vascular Surgery. He maintains his interest in theses area through his position as an honorary doctor of acute clinical medicine at Edinburgh Royal Infirmary.
Pursuing his interest in pharmacology, Howard took up a post as Clinical Research Physician at Quotient’s Phase I clinic in Edinburgh in 2008 and has been involved in significant numbers of Phase I/II studies in both clinical and scientific capacities, with a particular focus on First-in-Human studies. With an interest in pharmacokinetics, regulation, First-in-Human studies and translational medicine Howard has developed a keen expertise in early clinical development, especially the application of innovative approaches to continue the advancement of human therapeutics and human health by driving effectiveness within the development process.
Appearing: Day One, Wednesday 20 October 2010 8.50am Opening Remarks from Howard Goodall Howard Goodall, Clinical Research Physican - Phase I,
Quotient Bioresearch, Clinical Services 11.15am How to Fail Faster: Getting all the Answers in Phase I
- Combining novel technologies to create innovative study designs that allow a comprehensive understanding of drug molecules and attrition of unsuitable candidates as early as possible in clinical development.
- Use of AMS enabled approaches such as 14C light labelling and biomarker assessments of efficacy in SAD/MAD Phase I studies to allow a developer to move into Phase II with confidence in mechanism, and in depth knowledge of metabolic fate.
- Adaptive trial designs and flexible clinical protocols supported by flexible CMC strategies in Phase I, enabling real-time, “within-protocol” responses to emerging clinical data
- Use of patient populations to gain a greater understanding of drug viability in Phase I
Howard Goodall, Clinical Research Physican - Phase I,
Quotient Bioresearch, Clinical Services |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
